ANIP · ANI Pharmaceuticals Inc
United States · RS rating 25 · As of 2026-10-14
| Price | 70.16 USD |
|---|---|
| 1-day change | -1.0% |
| RS rating (overall / 1M / 3M / 12M) | 25 / 48 / 25 / 26 |
| Stage | Basing |
| Composite / Minervini / CANSLIM score | 27 / 18 / 30 |
| Industry group (rank) | Medical-Generic Drugs (94) |
| EPS growth Q/Q | +4.4% |
| Sales growth Q/Q | +8.4% |
| Distance from 52-week high | +26.4% |
| Market cap (USD) | $1.8B |